title: Reduction of G0 phase cells of colon cancer caco-2 cells may enhance 5-fluorouracil efficacy.
abstract: OBJECTIVE
  A major problem in the chemotherapy of colon caner may be due to those cells that are in residence in the G0 phase where they are less vulnerable to conventional therapy. To overcome this phenomenon, we attempted to recruit the reentry of these cells into the cell cycle via a signaling pathway that manipulates tumor growth.
  
  
  METHODS
  Epidermal growth factor (EGF) was used to stimulate colon cancer caco-2 cells. FACS analysis and proliferating cell nuclear antigen (PCNA) staining were used to estimate the cell cycle transition and cell proliferation activated by EGF, and a MTT assay was used to evaluate the synergistic effect of EGF and chemotherapy.
  
  
  RESULTS
  The percentage of caco-2 cells in the G0/G1 phase was significantly reduced by nearly 20% and the percentages in the S and G2/M phases were increased by EGF. The combined use of EGF and 5-fluorouracil (5-FU) enhanced the caco-2 cell chemosensitivity to 5-FU, reaching a maximum of an approximately threefold greater sensitivity than to 5-FU alone as judged by the 50% inhibiting concentration (IC50).
  
  
  CONCLUSIONS
  Our study demonstrated that stimulation by EGF enhanced the chemosensitivity of caco-2 cells to 5-FU, which may be a novel therapeutic protocol in colon cancer.
authors.affiliation: Department of Laproscope Surgery, Union Hospital affiliated to HuaZhong University of Science and Technology, WuHan 430022, China.
authors.forename: Lin
authors.initials: L
authors.lastname: Ye
authors.forename: Kaixiong
authors.initials: K
authors.lastname: Tao
authors.forename: Yang
authors.initials: Y
authors.lastname: Yu
authors.forename: Guobin
authors.initials: G
authors.lastname: Wang
keywords: chemosensitivity; dormant cells; epidermal growth factor; induction
references.citation: J Clin Oncol. 2002 Sep 15;20(18 Suppl):1S-13S
references.pmid: 12235219
references.citation: N Engl J Med. 2004 Jul 22;351(4):317-9
references.pmid: 15269308
references.citation: Exp Hematol. 2004 Feb;32(2):188-94
references.pmid: 15102480
references.citation: Ann Oncol. 2005 Jan;16(1):102-8
references.pmid: 15598946
references.citation: Leukemia. 2003 Oct;17(10):2049-51
references.pmid: 14513057
references.citation: Eur J Cancer. 2007 Jul;43(10):1502-7
references.pmid: 17524637
references.citation: Crit Rev Oncol Hematol. 2004 Jul;51(1):1-28
references.pmid: 15207251
references.citation: Trends Mol Med. 2005 Jul;11(7):327-35
references.pmid: 15950539
references.citation: Cancer Res. 2000 Mar 1;60(5):1225-8
references.pmid: 10728680
references.citation: Ann Oncol. 2006 Jun;17 Suppl 7:vii66-7
references.pmid: 16760297
references.citation: Semin Cancer Biol. 2007 Jun;17(3):191-203
references.pmid: 16762563
references.citation: Cancer Cell. 2008 Jan;13(1):7-9
references.pmid: 18167335
references.citation: Mol Cell Endocrinol. 2007 May 30;270(1-2):50-6
references.pmid: 17374439
references.citation: N Engl J Med. 2005 Feb 3;352(5):476-87
references.pmid: 15689586
references.citation: Nature. 1998 May 7;393(6680):83-5
references.pmid: 9590694
references.citation: Neoplasia. 2008 Mar;10(3):287-97
references.pmid: 18320073
references.citation: Am J Pathol. 2005 Oct;167(4):969-80
references.pmid: 16192633
references.citation: Am J Physiol Cell Physiol. 2005 Apr;288(4):C805-12
references.pmid: 15601754
references.citation: Crit Rev Oncol Hematol. 2007 Apr;62(1):53-61
references.pmid: 17324578
references.citation: J Biol Chem. 2002 May 17;277(20):17397-405
references.pmid: 11859072